PTC Therapeutics, Inc.
PTCT
株式のランク
#3375
PTC Therapeutics, Inc. (PTCT) is a biopharmaceutical company committed to the... PTC Therapeutics, Inc. (PTCT) is a biopharmaceutical company committed to the research, development, and commercialization of innovative therapies for patients afflicted with rare genetic disorders. Its robust pipeline encompasses both commercialized therapies and a variety of experimental drug candidates, spanning all stages of development—from early research and preclinical studies to clinical trials—with a primary focus on addressing various rare disease indications. Among its commercialized products, PTC Therapeutics provides Translarna and Emflaza, offering therapeutic options for Duchenne muscular dystrophy patients in the European Economic Area and the United States. Translarna also addresses nonsense mutation Duchenne muscular dystrophy in Brazil and Russia. The company additionally commercializes Tegsedi and Waylivra for various rare conditions throughout Latin America and the Caribbean. Furthermore, in Brazil, PTC Therapeutics distributes Evrysdi as a treatment for spinal muscular atrophy (SMA) in patients aged two months and older. Leveraging its proprietary splicing platform, the company is also actively developing PTC518, a promising therapeutic candidate aimed at treating Huntington's disease. To bolster its research and development capabilities, PTC Therapeutics has established strategic collaborations, including partnerships with F. Hoffman-La Roche Ltd and Hoffman-La Roche Inc., as well as the Spinal Muscular Atrophy Foundation, focusing on advancing drug discovery and development research, particularly in regenerative medicine. Additionally, it collaborates with Akcea Therapeutics, Inc. for the commercialization of Tegsedi and Waylivra in the Latin America and Caribbean region. Established in 1998, PTC Therapeutics, Inc. maintains its corporate headquarters in South Plainfield, New Jersey.
株価
$61.65
最終同期: 2026-10-19
時価総額
$5.15B
変化（1日）
4.07%
変化（1年）
-9.82%
国
US
取引 PTC Therapeutics, Inc. (PTCT)
カテゴリー
Healthcare
PTC Therapeutics, Inc.（PTCT）の利益
Jun 2026 時点の利益 TTM: $-67.07M
PTC Therapeutics, Inc. の最新の財務報告によると、同社の現在の利益は $-67.07M です。2023 年には $-696.11M の利益を上げ、これは 2022 年の利益 $-587.49M と 減少 です。このページに表示されている利益は、利息および税引き前利益、すなわち EBIT です。
PTC Therapeutics, Inc. の利益の推移（2011 〜 2026）
各年末の利益
| 年 | 利益 | 変化 |
|---|---|---|
| 2026 (TTM) | $-67.07M | -81.53% |
| 2024 | $-363.12M | -47.84% |
| 2023 | $-696.11M | 18.49% |
| 2022 | $-587.49M | 13.34% |
| 2021 | $-518.34M | 28.64% |
| 2020 | $-402.93M | 67.94% |
| 2019 | $-239.93M | 87.28% |
| 2018 | $-128.11M | 64.95% |
| 2017 | $-77.67M | -45.13% |
| 2016 | $-141.54M | -16.72% |
| 2015 | $-169.96M | 72.64% |
| 2014 | $-98.45M | 90.88% |
| 2013 | $-51.57M | 96.58% |
| 2012 | $-26.24M | -191.73% |
| 2011 | $28.60M | 0.00% |
同業他社の利益
| 企業 | 利益 | 利益の差 | 国 |
|---|---|---|---|
| $5.27B | -7,964.30% |
US
|
|
| $-3.09B | 4,502.38% |
US
|
|
| $-4.02B | 5,887.71% |
AU
|
|
| - | - |
CH
|
|
| $1.95B | -3,008.21% |
NL
|
